GSK email response on China compliance, March 2015

  • As we have previously said, we have increased our monitoring of expense claims and increased our compliance efforts in China.
  • We also engaged an independent legal firm and external consultancies to review our operations in China.
  • Based on the findings, we have taken disciplinary action against employees whose conduct contravened GSK's values and Code of Conduct. We have zero tolerance for this kind of behaviour.
  • They are not recent cases. The misconduct took place prior to mid-2013.
  • Regardless of scale, we will not tolerate misconduct. Where evidence of misconduct has been found, we take appropriate disciplinary action up to and including termination of employment.
  • GSK remains fully committed to China and has implemented fundamental policy reforms to ensure the company operates to the highest standards. We continue to look at our business in China and expect to make further investments in the country as we evolve our business model there to best meet the need of patients and customers in the country.